During the last few years, tumor necrosis factor-alpha (TNF-α) blocking agents (infliximab, etanercept, and adalimumab) have been used to treat chronic refractory uveitis in childhood [12–15] and, particularly, uveitis associated with JIA in children who have failed topical and second-line DMARD therapy [16, 17]. Here, TNF is linked to juvenile idiopathic arthritis.